Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yabao Pharmaceutical Group CoSHSE:600351 -3.53%70 Gross Margin % is 53.24% as of Mar. 2026, which is 7% below its 10-year median of 57.12. GuruFocus rates SHSE:600351 with a GF Score™ of 70/100 and a GF Value™ of ¥5.53 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 943 Drug Manufacturers companies, Yabao Pharmaceutical Group Co ranks better than 56.2% on this metric.
SHSE:600351's Gross Margin % is ranked better than 56.2% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs SHSE:600351: 52.58
Yabao Pharmaceutical Group Co had a gross margin of 53.24% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Yabao Pharmaceutical Group Co (SHSE:600351) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Yabao Pharmaceutical Group Co had a gross margin of 53.24% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Yabao Pharmaceutical Group Co Gross Margin % Related Terms
Yabao Pharmaceutical Group Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yabao Pharmaceutical Group Co Gross Margin % Chart
SHSE:600351 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Yabao Pharmaceutical Group Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yabao Pharmaceutical Group Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Yabao Pharmaceutical Group Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Yabao Pharmaceutical Group Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Yabao Pharmaceutical Group Co (SHSE:600351) has a Gross Margin % of 53.24% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Yabao Pharmaceutical Group Co and its competitors. This is near median its historical median of 57.12. Over the past decade, Yabao Pharmaceutical Group Co's Gross Margin % has ranged from 44.10 to 63.57. According to the industry distribution chart, Yabao Pharmaceutical Group Co ranks #413 out of 943 companies in the Drug Manufacturers industry, placing it in the top 43.8%.
Is Yabao Pharmaceutical Group Co's Gross Margin % too high?
Yabao Pharmaceutical Group Co's current Gross Margin % of 53.24% is near median its 10-year median of 57.12. Over the past 10 years, this metric has ranged from a low of 44.10 to a high of 63.57. The Drug Manufacturers industry median Gross Margin % is 48.54. Yabao Pharmaceutical Group Co's value of 53.24% is 9.7% above this industry median. Based on the distribution chart, Yabao Pharmaceutical Group Co ranks #413 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Yabao Pharmaceutical Group Co has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yabao Pharmaceutical Group Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Yabao Pharmaceutical Group Co ranks #413 out of 943 companies for Gross Margin %. This puts Yabao Pharmaceutical Group Co in the upper half of its industry. The industry median Gross Margin % is 48.54. Yabao Pharmaceutical Group Co's value of 53.24% is 9.7% above this benchmark. Historically, Yabao Pharmaceutical Group Co's own Gross Margin % has ranged from 44.10 to 63.57 over the past decade. While the company's 10-year median is 57.12 vs. the industry median of 48.54, Yabao Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yabao Pharmaceutical Group Co's current Gross Margin % of 53.24% is 9.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Yabao Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yabao Pharmaceutical Group Co's current Gross Margin % is 53.24%, which is near median its own 10-year median of 57.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yabao Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co (SHSE:600351) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.53, compared to a current price of ¥6.56 — trading 18.6% above its estimated fair value. The current Gross Margin % is 53.24%, which is near median its 10-year median of 57.12 and 9.7% above the Drug Manufacturers industry median of 48.54. Yabao Pharmaceutical Group Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Yabao Pharmaceutical Group Co (SHSE:600351), the current Gross Margin % is 53.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yabao Pharmaceutical Group Co (SHSE:600351) Overvalued in 2026?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥6.56 is trading 18.6% above its estimated GF Value™ of ¥5.53.
GuruFocus considers Yabao Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SHSE:600351:
Gross Margin %: 53.24% (near median its 10-year median of 57.12)
GF Value™: ¥5.53 vs. price of ¥6.56 (18.6% above fair value)
Industry Position: 9.7% above the Drug Manufacturers median (#413 of 943)
No single metric tells the full story. See the SHSE:600351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yabao Pharmaceutical Group Co Business Description
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
70GF Score
Get the complete analysis for SHSE:600351
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600351 has been successfully added to your 
